1. Home
  2. GRND vs STOK Comparison

GRND vs STOK Comparison

Compare GRND & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grindr Inc.

GRND

Grindr Inc.

HOLD

Current Price

$12.27

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$33.52

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GRND
STOK
Founded
2009
2014
Country
United States
United States
Employees
148
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.0B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
GRND
STOK
Price
$12.27
$33.52
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$19.67
$39.20
AVG Volume (30 Days)
1.2M
782.3K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
92.73
EPS
N/A
N/A
Revenue
N/A
$184,420,000.00
Revenue This Year
$23.08
N/A
Revenue Next Year
$17.04
$82.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
404.50
52 Week Low
$9.79
$5.35
52 Week High
$25.13
$40.22

Technical Indicators

Market Signals
Indicator
GRND
STOK
Relative Strength Index (RSI) 53.22 50.94
Support Level $11.83 $32.70
Resistance Level $12.90 $35.63
Average True Range (ATR) 0.46 2.34
MACD -0.07 -0.07
Stochastic Oscillator 39.19 69.05

Price Performance

Historical Comparison
GRND
STOK

About GRND Grindr Inc.

Grindr Inc is a social networking app for gay, bi, trans, and queer people. It is a social network that brings together gay and bisexual men who want to meet other men close to them in a completely discreet and anonymous way, without having to give any personal information or having to fill out a profile with confidential information in order to register.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: